Logo


Sun, Ranbaxy may be asked to sell some businesses for CCI approval to merger

Ranbaxy Laboratories and Sun Pharmaceutical Industries are likely to be advised to sell parts of their businesses before the Competition Commission of India (CCI) approves their merger. A source said the competition watchdog would by next month suggest "structural remedies" that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger. When contacted, both Sun Pharma and Ranbaxy refused to comment. On April 6, Sun Pharma announced it would buy Ranbaxy from Japan's Daiichi Sankyo in a $4-billion all-share ...